Chemically Evolved Integrin α5β1-Targeted Peptide PET Tracers for PDAC Detection

15 structurally evolved peptide analogues radiolabeled with gallium-68 were developed for PET/CT imaging of pancreatic ductal adenocarcinoma. The dataset likely contains results from systematic in vitro assays, microPET/CT imaging, and ex vivo biodistribution studies evaluating these tracers. Author Xin Gao published this data on figshare in May 2026.

Use Cases

• Comparing the stability and tumor uptake of different peptide analogues based on the described in vitro assays.
• Evaluating the preclinical potential of α5β1-targeted radiotracers for PDAC imaging based on microPET/CT and biodistribution results.
• Identifying lead compounds for further drug development based on the performance metrics of the 15 AV3 analogues.
• Studying the relationship between peptide chemical structure and imaging efficacy based on the alanine scanning and noncanonical amino acid engineering described.

Strengths

• Focuses on a specific, high-impact target (integrin α5β1) which is markedly upregulated in PDAC.
• Describes a systematic evaluation pipeline including in vitro assays, microPET/CT imaging, and ex vivo biodistribution.
• Compares a lead candidate ([68Ga]Ga-HKA-008) against a baseline ([68Ga]Ga-DOTA-AV3), showing enhanced stability and tumor uptake.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), indicating limited scope, likely summary results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Likely contains synthesized results from preclinical laboratory experiments.

Freshness

Last updated 2026-05-14 14:37:04; freshness should be verified.